News

BioSpace
biospace.com > press-releases > unravel-biosciences-and-the-scn2a-foundation-announce-drug-discovery-collaboration

Unravel Biosciences and The SCN2A Foundation Announce Drug Discovery Collaboration

Unravel Biosciences and The SCN2A Foundation Announce Drug Discovery Collaboration2+ hour, 43+ min ago   (450+ words) Unravel Biosciences and The SCN2A Foundation Announce Drug Discovery Collaboration'BioSpace Unravel Biosciences and The SCN2A Foundation Announce Drug Discovery Collaboration "PITTSBURGH--(BUSINESS WIRE)--#autism--The SCN2A Foundation today announced a research collaboration with Unravel Biosciences, Inc., an AI-enabled therapeutics company established to advance…...

BioSpace
biospace.com > press-releases > genyro-signs-exclusive-license-for-sidewinder-a-breakthrough-dna-construction-technology-featured-in-nature

Genyro Signs Exclusive License for “Sidewinder,” a Breakthrough DNA Construction Technology Featured in Nature

Genyro Signs Exclusive License for “Sidewinder,” a Breakthrough DNA Construction Technology Featured in Nature2+ day, 16+ min ago   (304+ words) A major technological advance in DNA writing enables researchers to construct and create in the language of biology SAN DIEGO, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Genyro Inc., a biotechnology company advancing next-generation DNA construction, today announced that it has entered into an…...

BioSpace
biospace.com > press-releases > lunai-bioworks-nasdaq-lnai-expands-nih-funded-ai-program-into-commercial-alcohol-use-disorder-drug-discovery

Lunai Bioworks (NASDAQ: LNAI) Expands NIH-Funded AI Program into Commercial Alcohol Use Disorder Drug Discovery

Lunai Bioworks (NASDAQ: LNAI) Expands NIH-Funded AI Program into Commercial Alcohol Use Disorder Drug Discovery2+ day, 1+ hour ago   (158+ words) AI Platform Achieves Key Milestones, Triggering Launch of Alcohol Use Disorder Program "These results underscore both the magnitude of unmet need in Alcohol Use Disorder and the commercial opportunity for biologically grounded, precision therapies," said David Weinstein, CEO of Lunai…...

BioSpace
biospace.com > press-releases > revvity-collaborates-with-lilly-to-expand-access-to-ai-drug-discovery-models

Revvity Collaborates with Lilly to Expand Access to AI Drug Discovery Models

2+ week, 6+ day ago   (471+ words) Revvity Collaborates with Lilly to Expand Access to AI Drug Discovery Models'BioSpace Revvity Collaborates with Lilly to Expand Access to AI Drug Discovery Models Collaboration funds participating biotechs to access Lilly predictive models through the Revvity Signals Xynthetica offering WALTHAM,…...

BioSpace
biospace.com > press-releases > bighat-biosciences-partners-with-lilly-to-advance-machine-learning-enabled-biologics-discovery-through-lilly-tunelab

BigHat Biosciences Partners With Lilly to Advance Machine-Learning-Enabled Biologics Discovery Through Lilly TuneLab

3+ week, 4+ hour ago   (316+ words) BigHat Biosciences Partners With Lilly to Advance Machine-Learning-Enabled Biologics Discovery Through Lilly TuneLab'BioSpace BigHat Biosciences Partners With Lilly to Advance Machine-Learning-Enabled Biologics Discovery Through Lilly TuneLab SAN MATEO, Calif.--(BUSINESS WIRE)--BigHat Biosciences, a protein therapeutics company that combines state-of-the-art…...

BioSpace
biospace.com > policy > as-fda-deploys-agentic-ai-pharma-begins-testing-the-next-frontier-of-intelligent-automation

As FDA Deploys Agentic AI, Pharma Begins Testing the Next Frontier of Intelligent Automation

1+ mon, 2+ week ago   (275+ words) The FDA's recent announcement of the deployment of agentic AI capabilities for all agency employees underpins the life sciences move toward the next evolution of AI capabilities. "Agentic AI refers to advanced artificial intelligence systems designed to achieve specific goals…...

BioSpace
biospace.com > drug-development > ai-in-car-t-development-lessons-from-the-front-lines

AI in CAR T Development: Lessons From the Front Lines

3+ mon, 2+ week ago   (392+ words) As the field advances, Smith said he anticipates that new challenges around data management and utilization will arise. However, he added that he sees both opportunity and complexity ahead for AI in CAR T therapy development. "As more and more…...

BioSpace
biospace.com > drug-development > opinion-can-ai-clinical-trial-technology-deliver-on-its-promise

Opinion: Can AI Clinical Trial Technology Deliver on Its Promise?

3+ mon, 2+ week ago   (390+ words) As a senior director at eClinical Solutions, which provides clients with an AI-enabled clinical trial data platform, I don't need to be convinced of the potential of machine learning to facilitate drug development. But I fear that if not implemented…...

BioSpace
biospace.com > business > drugmakers-hail-early-wins-in-ai-driven-transformation-of-manufacturing

Drugmakers Hail Early Wins in AI-Driven Transformation of Manufacturing

5+ mon, 3+ day ago   (506+ words) Taylor Tieden for BioSpace The term AI is used to refer to a wide range of technologies, from machine learning systems that analyze images to large language models that help companies manage and interpret complex datasets. While older computational technologies…...

BioSpace
biospace.com > policy > why-ai-wont-save-the-90-of-clinical-trials-that-still-fail

Why AI Won't Save the 90% of Clinical Trials That Still Fail

5+ mon, 1+ week ago   (129+ words) > Listen on Spotify> Listen on Apple Podcasts> Listen on Amazon Music> Listen on iHeart While AI represents a significant advancement in efficiency for early-stage drug discovery, it won't dramatically change the 90% clinical trial failure rate. Most failures stem from fundamental…...